Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) have been given an average rating of “Hold” by the ...

We recently published a list of 10 Cheapest Stocks Insiders Are Buying Recently. In this article, we are going to take a look at where Zentalis Pharmaceuticals (NASDAQ:ZNTL) stands against other ...

Zentalis Pharmaceuticals LLC shares tumbled to a 52-week low, touching down at $1.76, as the biopharmaceutical company grapples with a challenging market environment. According to InvestingPro ...

Access to a live webcast of the TD Cowen and Leerink events, as well as an archived recording, will be available under the “Events & Presentations” tab on the Investors & Media section of the ...

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) is projected to announce its earnings results before the market opens on Tuesday, February 25th.Analysts expect the company to announce ...

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small ...

Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib. The clinical-stage ...

Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Zentalis Pharmaceuticals (NASDAQ:ZNTL) stands against other cheapest stocks that insiders are buying recently. Why should we be interested in ...